EPM2A Antikörper (Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin)) Primary Antibody
(1 reference)
-
- Target Alle EPM2A Antikörper anzeigen
- EPM2A
-
Reaktivität
- Säugetier
-
Wirt
- Maus
-
Klonalität
- Monoklonal
-
Konjugat
- Dieser EPM2A Antikörper ist unkonjugiert
-
Applikation
- Immunostaining (ISt), Immunohistochemistry (IHC), Western Blotting (WB)
- Produktmerkmale
- Rare Disease
- Aufreinigung
- TC Supernatant: Hybridoma tissue-culture supernatant (5mL) containing 20-40 µg/mL monoclonal antibody (mAb).
- Klon
- N84-37
- Isotyp
- IgG1
-
anti-Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A) (AA 101-199) antibody Primary Antibody
EPM2A Reaktivität: Human ELISA, WB Wirt: Maus Monoclonal 6C6 unconjugated
anti-Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A) (C-Term) antibody Primary AntibodyEPM2A Reaktivität: Human ICC, IF, IHC (p), WB Wirt: Kaninchen Polyclonal unconjugated
anti-Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A) (Internal Region) antibody Primary AntibodyVerified EPM2A Reaktivität: Human IHC, ELISA, WB Wirt: Ziege Polyclonal unconjugated
anti-Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A) (AA 243-331) antibody Primary AntibodyEPM2A Reaktivität: Human EIA, WB Wirt: Maus Monoclonal k2A3 unconjugated
anti-Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A) (AA 1-331) antibody Primary AntibodyEPM2A Reaktivität: Human IP, WB Wirt: Kaninchen Polyclonal unconjugated
anti-Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A) (C-Term) antibody Primary AntibodyEPM2A Reaktivität: Human EIA, IHC (p), WB Wirt: Kaninchen Polyclonal unconjugated
anti-Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A) (Internal Region) antibody (Biotin) Primary AntibodyVerified EPM2A Reaktivität: Human ELISA, IHC, WB Wirt: Ziege Polyclonal Biotin
anti-Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A) (N-Term) antibody Primary AntibodyEPM2A Reaktivität: Human, Ratte, Rind (Kuh), Hund, Schwein, Kaninchen WB Wirt: Kaninchen Polyclonal unconjugated
anti-Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A) (N-Term) antibody Primary AntibodyEPM2A Reaktivität: Human, Maus, Ratte, Rind (Kuh), Hund, Schwein, Kaninchen WB Wirt: Kaninchen Polyclonal unconjugated
anti-Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A) (AA 101-199) antibody Primary AntibodyEPM2A Reaktivität: Human ELISA, WB Wirt: Maus Polyclonal unconjugated
-
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
-
-
: "A bioassay for Lafora disease and laforin glucan phosphatase activity." in: Clinical biochemistry, Vol. 46, Issue 18, pp. 1869-76, (2013) (PubMed).
-
: "A bioassay for Lafora disease and laforin glucan phosphatase activity." in: Clinical biochemistry, Vol. 46, Issue 18, pp. 1869-76, (2013) (PubMed).
-
- Target
- EPM2A
- Andere Bezeichnung
- Laforin (EPM2A Produkte)
- Synonyme
- TG-B, Tg(TcraK,TcrbK)TG-BFlv, EPM2, MELF, laforin, EPM2A, laforin glucan phosphatase, epilepsy, progressive myoclonic epilepsy, type 2 gene alpha, EPM2A, Epm2a
- UniProt
- O95278
- Pathways
- Cellular Glucan Metabolic Process
